Division of Rheumatology, Gulhane School of Medicine, Ankara, Turkey.
Clin Exp Rheumatol. 2013 May-Jun;31(3 Suppl 77):77-83. Epub 2013 Sep 9.
The Behçet's Syndrome Activity Score (BSAS) is the first patient reported outcome measure developed to assess the global disease activity in patients with Behçet's syndrome (BS). We aimed to evaluate the reliability and validity of the Turkish version of BSAS for measuring disease activity in BS. We further investigated the performance of Routine Assessment of Patient Index Data (RAPID)3, a patient-reported index originally developed for rheumatoid arthritis, in BS patients.
Patients seen consecutively at a tertiary Rheumatology Centre were requested to complete BSAS and multidimensional health assessment questionnaire (MDHAQ). Besides, all attending physicians filled the Behçet's Disease Current Activity Form (BDCAF). Descriptive statistics and Pearson correlation coefficients were calculated accordingly for the reliability and validity assessments of BSAS.
A total of 104 patients completed all three assessments. The test-retest reliability of BSAS has a good level (ICC=0.84, 95% CI [0.69-0.94]). The mean scores for BSAS, BDCAF and RAPID3 were 39±20.8, 3.2±1.4 and 9.2±5.6, respectively. BSAS was correlated with BDCAF moderately (r=0.587), while it was moderately correlated with RAPID3 (r=0.648). The correlation between the RAPID3 and BDCAF was moderate (r=0.403), but lower as compared to the correlations between the other instruments.
We found that the BSAS has modest correlation with BDCAF and is a reliable and valid patient reported measure of disease activity that can be used to assess patients with BS. An outcome score composed of only patient-derived observations may have the additional advantage of being easier to use in a routine care setting. Demonstration of a moderate level of correlation between RAPID3 and BDCAF (close to the level of weak relationship), suggests that RAPID3 likely needs more investigations before recommending its use in BS.
贝赫切特综合征活动评分（BSAS）是第一个为评估贝赫切特综合征（BS）患者的整体疾病活动而开发的患者报告结局测量工具。我们旨在评估 BSAS 土耳其版本测量 BS 疾病活动的可靠性和有效性。我们进一步研究了最初为类风湿关节炎开发的患者报告指数常规评估患者指数（RAPID）3 在 BS 患者中的表现。
连续在一家三级风湿病中心就诊的患者被要求完成 BSAS 和多维健康评估问卷（MDHAQ）。此外，所有主治医生都填写了贝赫切特病当前活动表（BDCAF）。相应地，为了评估 BSAS 的可靠性和有效性，计算了描述性统计数据和 Pearson 相关系数。
共有 104 名患者完成了所有三项评估。BSAS 的测试-重测信度具有良好水平（ICC=0.84，95%CI[0.69-0.94]）。BSAS、BDCAF 和 RAPID3 的平均得分分别为 39±20.8、3.2±1.4 和 9.2±5.6。BSAS 与 BDCAF 中度相关（r=0.587），与 RAPID3 中度相关（r=0.648）。RAPID3 与 BDCAF 的相关性中等（r=0.403），但低于其他仪器之间的相关性。
我们发现 BSAS 与 BDCAF 中度相关，是一种可靠且有效的疾病活动患者报告测量工具，可用于评估 BS 患者。仅由患者衍生观察结果组成的结局评分可能具有在常规护理环境中使用更方便的额外优势。RAPID3 与 BDCAF 之间显示出中等水平的相关性（接近弱关系的水平），这表明在推荐 RAPID3 在 BS 中使用之前，还需要进一步研究。
